Tag Archives: Opdivo

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »

Nobel laureate behind Bristol-Myers’ I-O superstar Opdivo demands a bigger cut

Opdivo, the blockbuster cancer drug Bristol-Myers Squibb co-developed with Japan’s Ono Pharmaceutical, is a cash cow in the global market. But a Nobel laureate who helped create the drug isn’t happy with his cut. Tasuku Honjo, a Japanese immunologist and Nobel Prize winner for his identification of the immune cell protein PD-1, wants to renegotiate… Read More »